Belite Bio (BLTE) Stock Price, News & Analysis

Company Overview

Belite Bio, Inc. is a clinical-stage biotechnology company focused on developing novel small molecule therapies for ophthalmic diseases. The company’s proprietary drug delivery platform is designed to address degenerative retinal disorders by enabling targeted, sustained delivery of therapeutic agents directly to the back of the eye. Belite Bio’s research and development efforts center on leveraging oral and injectable small molecule formulations that may offer safety and manufacturing advantages over biologics commonly used in ophthalmology.

The company’s pipeline is led by BLD-001, an intravitreally administered small molecule candidate in clinical development for the treatment of neovascular age-related macular degeneration (wet AMD) and diabetic retinopathy. In addition to BLD-001, Belite Bio is advancing preclinical programs aimed at expanding its portfolio to include treatments for geographic atrophy and diabetic macular edema. The modular nature of the platform allows for rapid iteration on drug candidates and may shorten development timelines.

Belite Bio completed its business combination with 2801 Pharma Acquisition Corp. in late 2021, resulting in its listing on the Nasdaq Stock Market under the ticker symbol “BLTE.” Headquartered in San Jose, California, the company operates research facilities in the United States and maintains collaborations with academic and clinical partners to support its trial programs. Its operations are primarily focused on North America, with plans to seek regulatory approval globally upon successful clinical outcomes.

Under the leadership of Chief Executive Officer Kenneth T. Barton, Belite Bio’s management team brings experience in ophthalmology drug development, regulatory strategy and commercialization. The company continues to build its organizational capabilities in anticipation of advancing multiple candidates through mid- and late-stage clinical trials.

Key Stats

• Today's Range: $60.47 to $61.55
• 50-Day Range: $56.81 to $67.29
• 52-Week Range: $43.70 to $86.53
• Volume: 30,551 shs
• Average Volume: 47,457 shs
• Market Capitalization: $1.94 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $96.67
• Consensus Rating: Buy

Belite Bio Stock Analysis - MarketRank™

Belite Bio scored higher than 36% of companies evaluated by MarketBeat, and ranked 740th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Belite Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Belite Bio has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Belite Bio are expected to grow in the coming year, from ($1.17) to ($0.83) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Belite Bio is -44.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Belite Bio is -44.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Belite Bio has a P/B Ratio of 12.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.60% of the float of Belite Bio has been sold short.

Short Interest Ratio / Days to Cover

Belite Bio has a short interest ratio ("days to cover") of 4.3.

Change versus previous month

Short interest in Belite Bio has recently increased by 5.44%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Belite Bio does not currently pay a dividend.

Dividend Growth

Belite Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.60% of the float of Belite Bio has been sold short.

Short Interest Ratio / Days to Cover

Belite Bio has a short interest ratio ("days to cover") of 4.3.

Change versus previous month

Short interest in Belite Bio has recently increased by 5.44%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

News Sentiment

Belite Bio has a news sentiment score of -0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Belite Bio this week, compared to 3 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Belite Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.29% of the stock of Belite Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 0.53% of the stock of Belite Bio is held by institutions.

BLTE Stock Analysis - Frequently Asked Questions

How have BLTE shares performed this year?

Belite Bio's stock was trading at $63.10 at the beginning of 2025. Since then, BLTE shares have decreased by 3.5% and is now trading at $60.92.

How were Belite Bio's earnings last quarter?

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) announced its earnings results on Monday, March, 17th. The company reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by $0.02.
Read the conference call transcript.

When did Belite Bio IPO?

Belite Bio (BLTE) raised $36 million in an IPO on Friday, April 29th 2022. The company issued 6,000,000 shares at $5.50-$6.50 per share.

Who are Belite Bio's major shareholders?

Top institutional investors of Belite Bio include GAMMA Investing LLC.

How do I buy shares of Belite Bio?

Shares of BLTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Belite Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Belite Bio investors own include Paycom Software (PAYC), Centrus Energy (LEU), Planet Labs PBC (PL), uniQure (QURE), Grayscale Ethereum Trust (ETH) (ETHE), Marathon Oil (MRO) and Vale (VALE).

Company Calendar

• Last Earnings: 3/17/2025
• Today: 7/19/2025
• Next Earnings (Estimated): 8/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BLTE
• CIK: 1889109
• Web: belitebio.com
• Phone: 858-246-6240
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Belite Bio: $96.67
• High Price Target: $110.00
• Low Price Target: $80.00
• Potential Upside/Downside: +58.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.36)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$36.14 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -32.07%
• Return on Assets: -30.91%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 24.31
• Quick Ratio: 24.31

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.72 per share
• Price / Book: 12.91

Miscellaneous

• Outstanding Shares: 31,840,000
• Free Float: 27,607,000
• Market Cap: $1.94 billion
• Optionable: Not Optionable
• Beta: -1.50